HIV/AIDS Skepticism

Pointing to evidence that HIV is not the necessary and sufficient cause of AIDS

Further HIV/AIDS Enlightenment out of Italy

Posted by Henry Bauer on 2010/10/21

That HIV does not cause AIDS is again demonstrated, this time in a doctoral thesis, “Endogenous retroviruses as confounding factors in the pathogenesis of AIDS”, by Chiara Matteuzzi, mentored by Dr. Stefania Pacini and Dr. Marco Ruggiero. The work has just been accepted (with maximum marks) at the University of Florence, is in English, and is publicly available. The presentation was in Italian.
The literature review mentions Montagnier’s longstanding view that sound immune systems withstand HIV, unpublished work of Dr. Christl Meyer suggesting that HIV is an evolutionary adapted and partly active variable and heritable gene construct of our immune (MHC/HLA)-system, De Harven’s discussion of human endogenous retroviruses as confounding factors in AIDS pathogenesis, and Yamamoto’s demonstration that stimulation of the immune system can eradicate HIV.
The experimental part of the thesis built on Yamamoto’s work, as described in the Abstract:
We demonstrated that GcMAF stimulated human monocyte proliferation and survival and  that this response was associated with VDR gene polymorphisms. Since these results were obtained in  peripheral blood mononuclear cells, an interplay between lymphocytes expressing VDR and GcMAF- stimulated monocytes producing vitamin D has to be assumed. The effect was dose-dependent and maximal  stimulation was achieved using 100 pg/ml. GcMAF sustained cell viability for about 98 h whereas un- stimulated cells were no longer viable after 48 h, as if GcMAF had rescued monocytes from apoptosis.  Heparin inhibited the stimulatory effect of GcMAF by binding the N-acetylgalactosamine moiety of  GcMAF. GcMAF stimulated cAMP formation in a dose-dependent manner. GcMAF inihibited PGE 2 – and  MCF-7 (human breast cancer cell)-stimulated angiogenesis in chick embryo chorionallantoic membrane  (CAM) assay.   Discussion
GcAMF-induced increase of cAMP formation could account for its anti-angiogenetic effect  since it was demonstrated that elevated cAMP level inhibited angiogenesis in CAM assay (J Vasc Res  31:195-204, 1994). GcMAF-induced inhibition of angiogenesis could then be crucial in determining its  therapeutic effects in conditions where angiogenesis plays a key role in the progression of the disease, from  cancer (Exp Cell Res 316:1304-8, 2010) to HIV infection (Angiogenesis 5: 141–151, 2002). In addition, the  CAM assay proved to be a rapid, simple and inexpensive method to determine the relative potencies of  different GcMAF preparations and their stability; for example, we observed that storage at room temperature  for 15 days decreased GcMAF potency by about 50%. These data could prove useful for upcoming clinical  trials on GcMAF. In fact, GcMAF is being sold over the internet and it appears that several people are  already assuming GcMAF to treat diseases as diverse as cancer and HIV infection.”

5 Responses to “Further HIV/AIDS Enlightenment out of Italy”

  1. mo79uk said

    Thanks for this, I’m going to read the Matteuzzi paper with great interest.

  2. Ken said

    I’ve read the articles on the GcMAF and everything I’ve found so far looks great. So the big question how do patients get it in America? And why is this not in headline news? A cure for HIV and some cancers sounds like a break through to me, but the media is silent. Big Pharma can’t make money off of curing people I guess, anyway if anyone finds info on how to get a hold of GcMAF in America please let all know where and how, Thanks

  3. Your doctor may be able to get GcMAF from the folks at but they find that it doesn’t seem to work on everyone. So I suggest that in that case you find someone for whom it does work and infuse their white blood cells, presumably including macrophages into the patient. This is done by separation via centrifuge and is called apheresis. It runs a risk of GVHD, Graft Versus Host Disease, which is a big deal though apparently that risk is minimized by using the a donor with the same blood type but differing HLA type. This apheresis procedure is well known and is used in cases where a bacterial infection is not conquered by antibiotics.

  4. mo79uk said

    I read that paper and forgot to comment here on it. A line I found interesting was:

    ‘Paricalcitol [a vitamin D analogue] evoked a stimulatory response quite similar to that of GcMAF and intracellular cAMP [an antimicrobial peptide] formation was strongest in the homozygous “FF/bb” genotype and non significant in the homozygous “ff/BB” genotype.’

    Essentially, these things work as long as there’s no dysfunction in the VDR.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: